Stretch Marks Fading: Drugs That Cause or Treat It

Stretch marks are dermal scars, not a single disease with one drug indication. Striae rubrae are the early, red-to-purple, sometimes raised or itchy phase. Striae albae are the mature, flat, white or silvery phase that follows once inflammation resolves. This distinction, more than any specific drug name, determines whether a pharmacologic intervention has a realistic chance of changing the outcome.

Several drug classes discussed below are not interchangeable and should not be confused with each other: tretinoin (all-trans retinoic acid, a topical retinoid sold under names like Retin-A, Renova, and Avita) is FDA-approved for acne and photoaging and used off-label for early striae; topical and systemic corticosteroids (for example clobetasol, betamethasone, or oral prednisone) are anti-inflammatory drugs that can cause striae as a side effect; anabolic androgenic steroids are synthetic testosterone derivatives used illicitly or off-label for muscle building, not a treatment for stretch marks; and topical hyaluronic acid is a skin-hydrating cosmetic ingredient, distinct from injectable hyaluronic acid dermal fillers or joint injections.

The core answer, with its boundary

Striae rubrae generally responds better to drug and procedural treatment than striae albae, because the tissue is still vascularized and metabolically active in the early phase. Topical tretinoin (0.025% to 0.1%), used off-label, has the strongest trial evidence for striae rubrae: two small randomized trials reported reduced striae length and width, and improved clinical severity scores, over three to six months of nightly use 10 11. Those trials involved fewer than 25 patients each and have not been replicated at scale, so the effect size should be treated as a signal rather than a settled number. No drug reliably improves mature striae albae; for that stage, the evidence favors procedural treatments such as fractional laser, sometimes paired with a topical agent.

How stretch marks form and why they fade

Rapid skin stretching, hormonal shifts, or drug exposure can tear the dermal connective tissue matrix. The initial inflammatory response produces striae rubrae 1. Over the following months to roughly two years, inflammation resolves, blood vessels recede, and collagen remodeling replaces the inflamed tissue with pale, atrophic scar tissue: striae albae. This natural fading is what most people notice as stretch marks "going away," though the marks rarely disappear entirely.

Once striae mature to albae, the dermis has lost elastin fibers and reorganized collagen into dense, low-cellularity scar tissue 2. That structural change is difficult to reverse with a topical drug alone, which is why timing (how old the mark is) matters more than which specific product is chosen.

Cortisol inhibits fibroblast proliferation and reduces dermal collagen and elastin synthesis. This is the mechanistic link between both endogenous hypercortisolism (Cushing syndrome) and exogenous corticosteroid therapy on one hand, and striae formation on the other. Estrogen, relaxin, and adrenal androgens during puberty and pregnancy also shift dermal matrix turnover 3.

Drugs that cause stretch marks

Corticosteroids, topical and systemic

Corticosteroids are the most common drug cause of striae. They suppress fibroblast activity, reduce glycosaminoglycan synthesis, and thin the epidermis and dermis 4.

High-potency topical corticosteroids (clobetasol propionate 0.05%, betamethasone dipropionate 0.05% under occlusion) can produce striae within weeks when applied to thin-skinned areas such as the groin, axillae, or inner arms, particularly with occlusive dressings or prolonged use. This is a recognized, dose- and potency-dependent cutaneous adverse effect of glucocorticoid therapy rather than a rare idiosyncratic reaction 4.

Systemic corticosteroids appear to carry dose-dependent risk, and younger patients may be more susceptible than older patients on similar regimens, based on retrospective cohort data on corticosteroid-related adverse events 5. Exact incidence figures vary between studies and populations; a clinician managing an individual patient's steroid dose and duration is better positioned to weigh that risk than a general figure can convey.

Inhaled corticosteroids at standard asthma or COPD doses rarely cause striae. High-dose inhaled corticosteroid use over the long term has been associated with skin thinning in systematic review data, but clinically apparent striae remain uncommon with inhaled formulations 6.

Safety note: systemic corticosteroids should never be stopped abruptly without medical guidance. Long-term use suppresses the adrenal glands, and sudden discontinuation can cause adrenal insufficiency, a medical emergency. Any tapering decision belongs to the prescribing clinician.

Anabolic androgenic steroids

Anabolic steroid use is linked to striae through two mechanisms: muscle hypertrophy that outpaces dermal elasticity, and direct hormonal effects on collagen metabolism. Survey-based data from strength-sport populations, summarized in an Endocrine Society scientific statement on performance-enhancing drugs, describe striae as a recognized cutaneous consequence of anabolic steroid use, concentrated over the deltoids, biceps, and pectorals 7. Because this evidence comes from self-reported survey data in athletic and bodybuilding populations rather than controlled trials, exact prevalence percentages should be treated as approximate rather than precise.

Supraphysiologic testosterone doses appear to carry higher risk than replacement-dose testosterone therapy, though controlled comparative data are limited. The likely explanation combines androgen effects on dermal collagen with the rate of muscle tissue expansion itself.

Other medications linked to striae

Hormonal contraceptives. Estrogen-progestin combinations may plausibly increase susceptibility in some individuals, but a cross-sectional study of 800 women found no statistically significant difference in striae prevalence between oral contraceptive users and nonusers after adjusting for BMI and parity 8. This is one of the clearer examples in this topic area where a commonly assumed drug-striae link is not well supported once confounders are controlled.

Antiretroviral protease inhibitors. Indinavir and ritonavir have been reported in case-level literature in association with striae, possibly through effects on retinoid metabolism and lipodystrophy-related body composition change 9. Case reports are a weaker form of evidence than cohort or trial data, so this association should be read as a documented occurrence, not a well-quantified risk.

Growth hormone therapy. Pediatric patients on recombinant human growth hormone occasionally develop striae during periods of rapid linear growth. Reported incidence in standard replacement protocols appears low, based on general clinical experience rather than a dedicated controlled study in the sources reviewed here.

Drugs used to treat stretch marks

No drug holds FDA approval specifically for striae prevention or treatment. Every option below is used off-label, and the supporting trials are mostly small.

Tretinoin (topical retinoid)

Tretinoin at 0.025% to 0.1% is the most-studied prescription topical for striae. It is thought to work by stimulating fibroblast collagen production, increasing epidermal thickness, and promoting angiogenesis in the superficial dermis 10.

In a randomized trial of 22 patients with early striae rubrae, six months of nightly tretinoin 0.1% cream produced measurable reductions in striae length and width along with histologic evidence of increased collagen I deposition, compared with no significant change in the vehicle group 10. A separate trial in 20 women with pregnancy-related striae found that three months of tretinoin 0.1% reduced clinical severity scores substantially more than placebo 11. Both trials are small and the exact percentage improvements reported in each should be treated as single-study estimates rather than a reliable population-level effect size; independent replication at larger scale has not been established in the sources reviewed here.

Tretinoin's effect on mature striae albae is minimal. It appears to work best when started within roughly the first year after a mark appears, while the tissue is still vascularized.

Tretinoin is FDA pregnancy category X and should not be used during pregnancy or breastfeeding. Common side effects include redness, peeling, and photosensitivity at the application site.

Topical hyaluronic acid

One randomized trial comparing a 0.1% hyaluronic acid preparation, vitamin E oil, and an untreated control in 60 patients with striae rubrae over 12 weeks found significantly greater improvement in striae color, atrophy, and overall severity with hyaluronic acid than with either comparator 12. This is a single trial; it supports hyaluronic acid as a reasonable option for people who cannot or prefer not to use a retinoid, not as an established first-line therapy on par with tretinoin.

Centella asiatica (gotu kola) preparations

Centella asiatica extracts have been studied mainly for preventing pregnancy-related striae, not treating existing ones. A Cochrane review of topical preparations for stretch mark prevention found mixed results across two Centella-based cream trials: one showed a statistically significant reduction in new stretch mark development, the other showed no benefit over placebo 13. For treating already-established striae, evidence is limited to laboratory data showing Centella triterpenes stimulate collagen synthesis in cultured fibroblasts; no adequately powered clinical trial for treatment (as opposed to prevention) was identified in the sources reviewed here.

Vitamin E and cocoa butter

Despite widespread consumer use, neither has demonstrated benefit in controlled trials. The Cochrane review found no significant benefit for cocoa butter lotion over placebo in preventing striae gravidarum across two trials totaling 305 women 13, and a separate small trial found no improvement from vitamin E oil over placebo for existing striae 12.

Combining drug therapy with procedures

Topical drugs often perform best paired with energy-based devices that create controlled dermal injury, targeting both the superficial and deep components of a stretch mark.

Tretinoin plus pulsed dye laser. For striae rubrae, the 585 to 595 nm pulsed dye laser reduces erythema and stimulates collagen remodeling. A comparative study of 40 patients found greater improvement at six months with combined pulsed dye laser and topical tretinoin than with either treatment alone 14.

Fractional lasers. Fractional CO2 and erbium:YAG lasers create microscopic columns of thermal injury that trigger a wound-healing collagen response. A systematic review covering 17 studies concluded that fractional laser therapy improves the clinical appearance of both striae rubrae and striae albae, with effect sizes described as moderate to large 15. This is the strongest evidence base currently available for treating mature striae albae, where topical drugs alone have little effect.

Post-laser adjuncts. Applying growth factors, platelet-rich plasma, or hyaluronic acid into laser-created microchannels may enhance outcomes. A randomized split-body study of 30 patients found greater improvement in striae width with fractional CO2 plus topical platelet-rich plasma than with fractional CO2 alone 16. Whether standalone topical platelet-rich plasma (without a device creating microchannels) offers any benefit is not established.

Microneedling. A randomized trial of 45 patients with striae albae found greater improvement in striae severity at 12 weeks when microneedling was combined with topical vitamin C serum than with microneedling alone 17. Microneedling is generally less expensive than laser and is a reasonable middle option where laser access is limited.

When drug-induced stretch marks warrant medical evaluation

New, wide (greater than roughly 1 cm), purple striae in someone not on exogenous corticosteroids should prompt evaluation for Cushing syndrome. The Endocrine Society's clinical practice guideline on diagnosing Cushing syndrome recommends screening with 24-hour urinary free cortisol, late-night salivary cortisol, or an overnight low-dose dexamethasone suppression test when wide, violaceous striae appear alongside other features suggestive of hypercortisolism, such as unexplained weight gain concentrated centrally, new hypertension, muscle weakness, or easy bruising 18.

Striae appearing before puberty, striae crossing dermatome boundaries, and rapidly progressive striae without an obvious mechanical cause also warrant an endocrine workup. A full drug history should include every route of corticosteroid exposure: oral, topical, inhaled, intranasal, intra-articular injection, and even compounded topical creams a patient may not think to mention.

If a corticosteroid is the identified cause, dose reduction or discontinuation under medical supervision, when clinically safe to do so, may allow early striae rubrae to partially improve. Established striae albae are generally regarded as a permanent structural change that discontinuing the drug will not reverse 1.

Emerging and low-evidence approaches

Topical silicone gel, widely used for hypertrophic scars, has been tested for striae in two small pilot studies, showing modest improvement in texture but not in pigmentation or width. The evidence is not sufficient to recommend silicone for striae outside general scar management 19.

Botulinum toxin A microinjections were explored in a single pilot study of 10 patients with striae rubrae, based on the idea that relaxing underlying muscle tension reduces mechanical stress on healing tissue. Preliminary improvement was reported at three months, but a 10-patient pilot cannot support a clinical recommendation either way 20.

What is established, what is plausible, and what is not established

Established: corticosteroids (topical and systemic) and anabolic androgenic steroids are documented causes of striae, acting through suppressed dermal collagen and elastin synthesis. Striae rubrae has a meaningfully better response to intervention than striae albae. No drug is FDA-approved specifically for stretch marks.

Plausible but not firmly established: topical tretinoin's benefit for early striae rubrae, based on two small randomized trials; topical hyaluronic acid's benefit, based on one trial; combination laser-plus-topical protocols outperforming either alone, based on small comparative studies.

Not established: any drug producing meaningful improvement in mature striae albae; standalone topical PRP without a device creating microchannels; silicone gel or botulinum toxin for striae; a consistent, well-quantified anabolic-steroid striae incidence rate; and any oral contraceptive-striae link once BMI and parity are accounted for.

A decision framework for choosing a stretch mark approach

This framework is meant to organize the decision, not replace an individual evaluation by a prescribing clinician or dermatologist.

Frequently asked questions

Percentage figures drawn from single small trials are noted here as single-study estimates rather than established effect sizes, and reported figures vary between studies and have not been independently confirmed here.